TYRA Tyra Biosciences Inc
Price (delayed)
$8.65
Market cap
$459.23M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.51
Enterprise value
$372.48M
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective
Highlights
The EPS is up by 7% year-on-year and by 6% since the previous quarter
The debt has declined by 4.2% year-on-year
Tyra Biosciences's quick ratio has soared by 76% YoY but it has decreased by 20% from the previous quarter
Tyra Biosciences's equity has surged by 68% YoY but it has decreased by 5% QoQ
TYRA's net income is down by 25% YoY and by 3.3% QoQ
Key stats
What are the main financial stats of TYRA
Market
Valuations
Earnings
Shares outstanding
53.09M
Market cap
$459.23M
Enterprise value
$372.48M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.28
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$104.18M
Net income
-$86.48M
EBIT
-$86.48M
EBITDA
-$85.96M
Free cash flow
-$70.44M
Per share
Balance sheet
Liquidity
EPS
-$1.51
EPS diluted
-$1.51
Free cash flow per share
-$1.23
Book value per share
$6.78
Revenue per share
$0
TBVPS
$6.35
Total assets
$363.56M
Total liabilities
$20.41M
Debt
$6.22M
Equity
$343.15M
Working capital
$332.87M
Debt to equity
0.02
Current ratio
23.81
Quick ratio
23.46
Net debt/EBITDA
1.01
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-22.4%
Return on equity
-23.5%
Return on invested capital
-35.8%
Return on capital employed
-24.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TYRA stock price
How has the Tyra Biosciences stock price performed over time
Intraday
-0.8%
1 week
-15.53%
1 month
-26.13%
1 year
-48.45%
YTD
-37.77%
QTD
-6.99%
Financial performance
How have Tyra Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$104.18M
Net income
-$86.48M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 30% YoY and by 4.1% from the previous quarter
TYRA's net income is down by 25% YoY and by 3.3% QoQ
Growth
What is Tyra Biosciences's growth rate over time
Valuation
What is Tyra Biosciences stock price valuation
P/E
N/A
P/B
1.28
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 7% year-on-year and by 6% since the previous quarter
Tyra Biosciences's equity has surged by 68% YoY but it has decreased by 5% QoQ
The P/B is 48% below the last 4 quarters average of 2.5
Efficiency
How efficient is Tyra Biosciences business performance
The return on invested capital has surged by 74% year-on-year and by 8% since the previous quarter
The ROE has grown by 22% YoY and by 6% from the previous quarter
The ROA has grown by 21% YoY and by 6% from the previous quarter
Dividends
What is TYRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TYRA.
Financial health
How did Tyra Biosciences financials performed over time
Tyra Biosciences's quick ratio has soared by 76% YoY but it has decreased by 20% from the previous quarter
The company's current ratio has surged by 73% YoY but it fell by 19% QoQ
The debt is 98% smaller than the equity
Tyra Biosciences's equity has surged by 68% YoY but it has decreased by 5% QoQ
The debt to equity has declined by 33% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.